AzurRx BioPharma Inc (NASDAQ:AZRX) was the recipient of a significant increase in short interest during the month of November. As of November 29th, there was short interest totalling 574,700 shares, an increase of 108.8% from the November 14th total of 275,200 shares. Based on an average daily volume of 338,900 shares, the short-interest ratio is presently 1.7 days. Currently, 2.8% of the company’s shares are short sold.
A number of brokerages have commented on AZRX. HC Wainwright set a $5.00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a research note on Friday, October 18th. Maxim Group set a $3.00 price target on shares of AzurRx BioPharma and gave the company a “buy” rating in a research note on Tuesday, October 15th. Six research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $7.10.
Shares of AzurRx BioPharma stock opened at $0.74 on Thursday. The stock has a 50 day moving average of $0.71 and a 200 day moving average of $1.09. The firm has a market capitalization of $21.06 million, a price-to-earnings ratio of -0.84 and a beta of 2.11. AzurRx BioPharma has a fifty-two week low of $0.42 and a fifty-two week high of $3.10.
Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of AzurRx BioPharma by 255.0% in the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock valued at $443,000 after purchasing an additional 186,985 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of AzurRx BioPharma during the 3rd quarter worth $51,000. JPMorgan Chase & Co. acquired a new stake in shares of AzurRx BioPharma during the 2nd quarter worth about $57,000. Royal Bank of Canada acquired a new stake in shares of AzurRx BioPharma during the 2nd quarter worth about $48,000. Finally, BlackRock Inc. raised its holdings in AzurRx BioPharma by 57.6% in the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock valued at $72,000 after buying an additional 15,463 shares during the period. Institutional investors own 9.85% of the company’s stock.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
See Also: Stock Symbol
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.